In this study, we demonstrated that among patients with NSCLC with a PD-L1 TPS ≥ 50%, despite varied pretreatment K-index, the PFS after pembrolizumab treatment was accurately predicted by the K-index. The gene discussed is CD274; the disease is non-small cell lung carcinoma.